Skip to main content

Table 1 Baseline characteristics of patients with NPC treated with or without Nimotuzumab

From: The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis

CharacteristicNimotuzumab Arm
N = 184(%)
No Nimotuzumab Arm
N = 546(%)
P value
Gender  0.704
 Female37(20.11)117(21.43) 
 Male147(79.89)429(78.57) 
Age, Mean (SD)43.92 (10.53)44.1 2(10.62)0.822
 <4495(51.63)253(46.34) 
  ≥ 4489(48.37)293(53.66) 
WHO pathology  0.436
 I3(1.6)11(2.0) 
 II8(4.3)14(2.6) 
 III173(94.1)521(95.4) 
T classification  0.966
 T15(2.72)17(3.11) 
 T216(8.70)42(7.69) 
 T3107(58.16)317(58.06) 
 T456(30.42)170(31.14) 
N classification  0.972
 No19(10.33)57(10.44) 
 N175(40.76)230(42.13) 
 N273(39.67)214(39.19) 
 N317(9.24)45(8.24) 
Clinical stage  0.937
 III116(63.04)346(63.37) 
 IVa51(27.72)155(28.39) 
 IVb17(9.24)45(8.24) 
Chemotherapy  0.684
 Concurrent61(33.15)190(34.80) 
 Induction + concurrent123(66.85)356(65.20)